Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

Published by: GBI Research

Published: Dec. 1, 2009 - 132 Pages


Table of Contents


1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Global Monoclonal Antibodies Market: Introduction
2.1 GBI Research Report Guidance
3 Global Monoclonal Antibodies Market: Market Characterization
3.1 Introduction
3.2 Revenue Forecasts for the Global MAbs Market Potential
3.2.1 MAbs Treatment Potential
3.2.2 Drug Prices
3.2.3 Market Potential
3.2.4 Market Potential Segmentation
3.3 Revenue Forecasts of Global MAbs Market - Actual Market
3.3.1 MAbs Actual Treatment Population
3.3.2 Actual Sales
3.3.3 Actual Sales Segmentation
3.4 Treatment Usage Patterns
3.5 Global MAbs Trends
3.5.1 Market Trends
3.5.2 Technology Trends
3.6 Product Trends
3.6.1 Research and Development Focus Shifted Towards Humanized and Fully Humanized MAbs
3.7 Global MAbs Market Drivers
3.7.1 Gradual Growth in the Uptake of MAbs Have Driven the Monoclonal Antibody Sales Growth
3.7.2 Improved Side-effect Profiles and Tolerance of MAbs Therapy
3.7.3 Lack of Effective Conventional Therapies Accelerates Utilization of MAbs
3.7.4 Expanded Indications Opens up New Potential Patient Group
3.7.5 Lack of Generics Augmented the Sales Growth of MAbs
3.8 Global MAbs Market Restraints
3.8.1 High Cost of MAbs Hampering the Growth of Treatment Population
3.8.2 Adverse Effects - Generation of Antibodies against MAbs in Patients Receiving Monoclonal Antibody Therapy
3.8.3 Industry Challenges - Majority of MAbs Receive Approvals as Last Option Therapies
3.9 Unmet Needs
3.9.1 The High Cost of MAb Therapies is the Major Unmet Need and it is Also Responsible for Low Utilization by Patients
3.9.2 MAbs Do Not Cure the Disease; They either Treat Signs and Symptoms or Decelerate Cell Proliferation
4 Global MAbs Market Potential: Therapeutic Distribution
4.1 MAbs Market Potential in HER2 Breast Cancer (Adjuvant and Metastatic)
4.1.1 Introduction
4.1.2 Prescription Population
4.1.3 Annual Cost of Therapy
4.1.4 Market Potential
4.2 MAbs Market Potential in Bone Metastases and Bone Loss Due to Cancer Therapy
4.2.1 Introduction
4.2.2 Prescription Population
4.2.3 Annual Cost of Therapy
4.2.4 Market Potential
4.3 MAbs Market Potential in Relapsing-remitting Multiple Sclerosis (RRMS)
4.3.1 Introduction
4.3.2 Prescription Population
4.3.3 Annual Cost of Therapy
4.3.4 Market Potential
4.4 MAbs Market Potential in Metastatic Non-Small Cell Lung Cancer (NSCLC)
4.4.1 Introduction
4.4.2 Prescription Population
4.4.3 Annual Cost of Therapy
4.4.4 Market Potential
4.5 MAbs Market Potential in Rheumatoid Arthritis
4.5.1 Introduction
4.5.2 Prescription Population
4.5.3 Annual Cost of Therapy
4.5.4 Market Potential
5 Global MAbs Market: Pipeline Analysis
5.1 Introduction
5.2 MAbs Nomenclature
5.3 Monoclonal Antibody Technology
5.4 Applications of MAbs
5.4.1 Detection Assays
5.4.2 Purification Techniques
5.4.3 Gene Identification
5.4.4 Applied Chemistry
5.4.5 Disease Therapy
5.5 Therapeutic Applications in Oncology
5.5.1 Introduction
5.5.2 Marketed Therapies
5.5.3 Therapies in Late Stage Pipeline
5.6 Therapeutic Applications in Autoimmune and Inflammatory Diseases
5.6.1 Introduction
5.6.2 Marketed Therapies
5.6.3 Therapies in Late Stage Pipeline
5.7 Therapeutic Applications in Respiratory Diseases
5.7.1 Introduction
5.7.2 Marketed Therapies
5.7.3 Therapies in Late Stage Pipeline
5.8 Therapeutic Applications in Infectious Diseases
5.8.1 Introduction
5.8.2 Marketed Therapies
5.8.3 Therapies in Pipeline
5.9 Therapeutic Applications in Organ Transplantation
5.9.1 Introduction
5.9.2 Marketed Therapies
5.10 Therapeutic Applications in Cardiovascular Diseases
5.10.1 Introduction
5.10.2 Marketed Therapies
5.10.3 Therapies in Pipeline
5.11 New Indications
5.11.1 Central Nervous System
5.11.2 Diabetes
5.12 Insights into Most Promising Drugs
5.12.1 Denosumab
6 Global MAbs Market: M&A Landscape
6.1 Overview
6.1.1 Emergent BioSolutions acquires Avanir Pharmaceuticals
6.1.2 MacroGenics acquires Raven Biotechnologies
6.1.3 Thermo Fisher acquires Affinity BioReagents
6.2 R&D Licensing Agreements
6.2.1 Deals by Phase
6.2.2 Deals by Geography
6.2.3 Deals by Licensing Type
6.2.4 Deals by Value ($)
6.2.5 Preclinical
6.2.6 Phase I
6.2.7 Phase II
6.2.8 Phase III
6.2.9 Approved
7 Global MAbs Market: Competitive Landscape
7.1 Evolving competitive landscape
7.1.1 Major players
7.1.2 Key MAbs in the Market
7.2 Company Benchmarking Analysis
7.3 Roche/Genentech
7.3.1 Key Monoclonal Antibody Drugs
7.3.2 Key Indications of Interest
7.3.3 Pipeline Analysis
7.4 Abbott
7.4.1 Key MAbs
7.4.2 Key Indications of Interests
7.4.3 Pipeline Analysis
7.5 Johnson & Johnson
7.5.1 Key MAbs
7.5.2 Key Indications of Interest
7.5.3 Pipeline Analysis
7.6 Biogen Idec.
7.6.1 Key MAbs
7.6.2 Key Indications of Interest
7.6.3 Pipeline Analysis
7.7 Merck/Schering Plough
7.7.1 Key MAbs
7.7.2 Key Indications of Interest
7.7.3 Pipeline Analysis
7.8 AstraZeneca
7.8.1 Key MAbs
7.8.2 Key Indications of Interest
7.8.3 Pipeline Analysis
7.9 Bristol-Myers Squibb
7.9.1 Key MAbs
7.9.2 Key Indications of Interest
7.10 Elan
7.10.1 Key MAbs
7.10.2 Key Indications of Interest
7.10.3 Pipeline Analysis
7.11 Eli Lilly
7.11.1 Key Monoclonal Antibody Drugs
7.11.2 Key Indications of Interests
7.11.3 Pipeline Analysis
7.12 Amgen
7.12.1 Key Monoclonal Antibody Drugs
7.12.2 Key Indications of Interest
7.12.3 Pipeline Analysis
8 Global MAbs Market: Appendix
8.1 Research Methodology
8.2 Geographical Scope
8.3 Coverage
8.4 Secondary Research
8.5 Primary Research
8.6 Forecasts
8.6.1 Epidemiology-based Forecasting
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer
1.1 List of Tables
Table 1: MAbs Market, Global, MAbs Treatment Potential, 2000-2008
Table 2: MAbs Market, Global, MAbs Treatment Potential, 2008-2015
Table 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2008
Table 4: MAbs Market, Global, Annual Cost of Therapy ($), 2008-2015
Table 5: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2008
Table 6: MAbs Market, Global, MAbs Market Potential ($ bn), 2008-2015
Table 7: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2008
Table 8: MAbs Market, Global, MAbs Actual Treatment Population, 2008-2015
Table 9: MAbs Market, Global, Actual Sales ($ bn), 2000-2008
Table 10: MAbs Market, Global, Actual Sales ($ bn), 2008-2015
Table 11: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2008
Table 12: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008-2015
Table 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2008
Table 14: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2008-2015
Table 15: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2008
Table 16: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2008-2015
Table 17: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2008
Table 18: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2008-2015
Table 19: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population, 2009-2015
Table 20: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015
Table 21: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn), 2009-2015
Table 22: MAbs Market, Global, RRMS, Treatment Options, 2008
Table 23: MAbs Market, Global, RRMS, Prescription Population, 2000-2008
Table 24: MAbs Market, Global, RRMS, Prescription Population, 2008-2015
Table 25: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2008
Table 26: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2008-2015
Table 27: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2008
Table 28: MAbs Market, Global, RRMS, Market Potential ($ bn), 2008-2015
Table 29: MAbs Market, Global, Metastatic NSCLC, Treatment Options, 2008
Table 30: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2008
Table 31: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2008-2015
Table 32: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2008
Table 33: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2008-2015
Table 34: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2008
Table 35: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2008-2015
Table 36: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2008
Table 37: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2008-2015
Table 38: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2008
Table 39: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2008-2015
Table 40: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2008
Table 41: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2008-2015
Table 42: MAbs Market, Global, Monoclonal Antibody Nomenclature
Table 43: MAbs Market, Global, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009
Table 44: MAbs Market, Global, Licensing Agreements for Drugs in the Phase I, 2008-2009
Table 45: MAbs Market, Global, Licensing Agreements for Drugs in the Phase II, 2008-2009
Table 46: MAbs Market, Global, Licensing Agreements for Drugs in the Phase III, 2008-2009
Table 47: MAbs Market, Global, Licensing Agreements for Approved Drugs, 2008-2009
Table 48: MAbs Market, Global, Top 5 Companies Sales ($m), 2006-2008
Table 49: MAbs Market, Global, Top 10 MAbs ($m), 2006-2008
Table 50: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015
Table 51: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015
Table 52: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015
Table 53: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015
Table 54: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015
Table 55: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015
Table 56: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015
Table 57: MAbs Market, Global, Elan Revenues ($ m), 2006-2015
Table 58: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015
Table 59: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015
1.2 List of Figures
Figure 1: MAbs Market, Global, Major Factors Influencing the Global MAbs Market, 2008
Figure 2: MAbs Market, Global, MAbs Treatment Potential, 2000-15
Figure 3: MAbs Market, Global, Annual Cost of Therapy ($), 2000-2015
Figure 4: MAbs Market, Global, MAbs Market Potential ($ bn), 2000-2015
Figure 5: MAbs Market, Global, Market Segmentation by Disease, 2008 and 2015
Figure 6: MAbs Market, Global, MAbs Actual Treatment Population, 2000-2015
Figure 7: MAbs Market, Global, Actual Sales ($ bn), 2000-2015
Figure 8: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2008 and 2015
Figure 9: MAbs Market, Global, Actual Sales Segmentation ($ bn), 2000-2015
Figure 10: MAbs Market, Global, Treatment Population Trends, 2000-2015
Figure 11: MAbs Market, Global, MAbs Segmented by Origin, 1992-2009
Figure 12: MAbs Market, Global, Market Share of Key Indications, 2008
Figure 13: MAbs Market, Global, HER2+ Breast Cancer, Prescription Population, 2000-2015
Figure 14: MAbs Market, Global, HER2+ Breast Cancer, Annual Cost of Therapy ($), 2000-2015
Figure 15: MAbs Market, Global, HER2+ Breast Cancer, Market Potential ($ bn), 2000-2015
Figure 16: MAbs Market, Global, Bone Metastasis and Bone Loss, Prescription Population, 2009-2015
Figure 17: MAbs Market, Global, Bone Metastasis and Bone Loss, Annual Cost of Therapy ($), 2009-2015
Figure 18: MAbs Market, Global, Bone Metastasis and Bone Loss, Market Potential ($ bn), 2009-2015
Figure 19: MAbs Market, Global, Multiple Sclerosis, Diseased Population, 2008
Figure 20: MAbs Market, Global, RRMS, Prescription Population, 2000-2015
Figure 21: MAbs Market, Global, RRMS, Annual Cost of Therapy ($), 2000-2015
Figure 22: MAbs Market, Global, RRMS, Market Potential ($ bn), 2000-2015
Figure 23: MAbs Market, Global, Metastatic NSCLC, Prescription Population, 2000-2015
Figure 24: MAbs Market, Global, Metastatic NSCLC, Annual Cost of Therapy ($), 2000-2015
Figure 25: MAbs Market, Global, Metastatic NSCLC, Market Potential ($ bn), 2000-2015
Figure 26: MAbs Market, Global, Rheumatoid Arthritis, Prescription Population, 2000-2015
Figure 27: MAbs Market, Global, Rheumatoid Arthritis, Annual Cost of Therapy ($), 2000-2015
Figure 28: MAbs Market, Global, Rheumatoid Arthritis, Market Potential ($ bn), 2000-2015
Figure 29: MAbs Market, Global, Pipeline Segmentation by Disease, 2009
Figure 30: MAbs Market, Global, Oncology Pipeline, 2009
Figure 31: MAbs Market, Global, Autoimmune Diseases Pipeline, 2009
Figure 32: MAbs Market, Global, Respiratory Diseases Pipeline by Phase of Development, 2009
Figure 33: MAbs Market, Global, Infectious Diseases Pipeline by Phase of Development, 2009
Figure 34: MAbs Market, Global, Organ Transplantation Pipeline by Phase of Development, 2009
Figure 35: MAbs Market, Global, Cardiovascular Pipeline by Phase of Development, 2009
Figure 36: MAbs Market, Global, Other New Indications in Pipeline, 2009
Figure 37: MAbs Market, Global Major M&A Deals, 2008-2009
Figure 38: MAbs Market, Global, Major Licensing Agreements by Phase, 2008-2009
Figure 39: MAbs Market, Global, Major Licensing Agreements By Geography, 2008-2009
Figure 40: MAbs Market, Global, Major Licensing Agreements By Deal Value, 2008-2009
Figure 41: MAbs Market, Global, Top Three Companies, 2008
Figure 42: MAbs Market, Global, Top 5 Companies Sales Trend, 2006-2008
Figure 43: MAbs Market, Global, Key Target Therapies Launched, 1997-2009
Figure 44: MAbs Market, Global, Company Market Share Analysis, 2008
Figure 45: MAbs Market, Global, Company Benchmarking Analysis, 2008
Figure 46: MAbs Market, Global, Top 10 MAbs, 2006-2008
Figure 47: MAbs Market, Global, Roche/Genentech Revenue Segmentation, 2008
Figure 48: MAbs Market, Global, Roche/Genentech Revenue ($ m), 2006-2015
Figure 49: MAbs Market, Global, Roche/Genentech R&D Pipeline by Therapeutic Area, November 2009
Figure 50: MAbs Market, Global, Roche/Genentech Pipeline Analysis by Phase, November 2009
Figure 51: MAbs Market, Global, Abbott Revenue Segmentation, 2008
Figure 52: MAbs Market, Global, Abbott Revenue ($ m), 2006-2015
Figure 53: MAbs Market, Global, Abbott Pipeline Analysis by Phase, November 2009
Figure 54: MAbs Market, Global, Johnson & Johnson Revenue ($ m), 2006-2015
Figure 55: MAbs Market, Global, Johnson & Johnson R&D Pipeline by Therapeutic Area, November 2009
Figure 56: MAbs Market, Global, Johnson & Johnson Pipeline Analysis by Phase, November 2009
Figure 57: MAbs Market, Global, Biogen Idec Revenue Segmentation, 2008
Figure 58: MAbs Market, Global, Biogen Idec Revenue ($ m), 2006-2015
Figure 59: MAbs Market, Global, Biogen Idec R&D Pipeline by Therapeutic Area, November 2009
Figure 60: MAbs Market, Global, Biogen Idec Pipeline Analysis by Phase, November 2009
Figure 61: MAbs Market, Global, Merck/Schering Plough Revenues ($ m), 2006-2015
Figure 62: MAbs Market, Global, Merck/Schering-Plough R&D Pipeline by Therapeutic Area, November 2009
Figure 63: MAbs Market, Global, Merck/Schering-Plough Pipeline Analysis by Phase, November 2009
Figure 64: MAbs Market, Global, AstraZeneca Revenues ($ m), 2006-2015
Figure 65: MAbs Market, Global, AstraZeneca R&D Pipeline by Therapeutic Area, November 2009
Figure 66: MAbs Market, Global, AstraZeneca Pipeline Analysis by Phase, November 2009
Figure 67: MAbs Market, Global, Bristol-Myers Squibb Revenues ($ m), 2006-2015
Figure 68: MAbs Market, Global, Bristol-Myers Squibb R&D Pipeline by Phase, November 2009
Figure 69: MAbs Market, Global, Elan Revenues ($ m), 2006-2015
Figure 70: MAbs Market, Global, Elan R&D Pipeline by Therapeutic Area, November 2009
Figure 71: MAbs Market, Global, Elan Pipeline Analysis by Phase, November 2009
Figure 72: MAbs Market, Global, Eli Lilly, Revenues ($ m), 2006-2015
Figure 73: MAbs Market, Global, Eli Lilly R&D Pipeline by Therapeutic Area, November 2009
Figure 74: MAbs Market, Global, Eli Lilly Pipeline Analysis by Phase, November 2009
Figure 75: MAbs Market, Global, Amgen Revenues ($ m), 2006-2015
Figure 76: MAbs Market, Global, Amgen R&D Pipeline by Therapeutic Area, November 2009
Figure 77: MAbs Market, Global, Amgen Pipeline Analysis by Phase, November 2009
Figure 78: GBI Research Methodology
Figure 79: GBI Research Market Forecasting Model

Abstract

Summary

GBI Research, the leading business intelligence provider, has released its latest research “The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global monoclonal antibodies market. The report analyzes the markets for monoclonal antibodies in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, annual cost of therapy and market potential are forecast until 2015 for select segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
  • Annualized market data for the monoclonal antibodies market from 2000 to 2008, forecast forward to 2015
  • Analysis of the potential for the monoclonal antibodies market in select therapeutic areas. These include HER2 breast cancer, bone metastases, multiple sclerosis, Non Small Cell Lung cancer (NSCLC) and Rheumatoid Arthritis
  • Market characterization of the monoclonal antibodies market including market size, annual cost of therapy, sales volume and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Abbott Laboratories, Johnson & Johnson, Merck & Co, Biogen Idec, AstraZeneca, Bristol -Myers Squibb, Elan Pharmaceuticals, Amgen Inc and Eli Lilly
  • Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global monoclonal antibodies market
Reasons to buy

The report will enhance your decision making capability. It will allow you to
  • Align product portfolio to the markets with high growth potential
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
  • Develop key strategic initiatives by understanding key focus areas of leading companies
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2012
2/14/2012 - 30